SGLT2 Inhibitors versus DPP4 Inhibitors: Lower Nephrolithiasis Risk Found in Diabetes Patients, Study Finds
Korea: A recent study published in Diabetes Care has explored the risk of nephrolithiasis (kidney stones) associated with two popular classes of medications used to treat type 2 diabetes: Sodium-glucose co-transporter 2 (SGLT2) inhibitors and dipeptidyl peptidase-4 (DPP4) inhibitors.
The study revealed a lower risk of nephrolithiasis with SGLT2 inhibitors than DPP4 inhibitors in both stone never-formers and ever-formers. The researchers, however, noted that the relative risk reduction was more pronounced in those without a history of kidney stones, and the absolute risk reduction was more significant in patients with a prior history of stone formation.
SGLT2 inhibitors and DPP4 inhibitors are commonly prescribed for managing type 2 diabetes, a condition that often leads to complications such as kidney disease. Both classes of drugs have demonstrated benefits in reducing blood sugar levels and improving cardiovascular outcomes. However, concerns regarding potential side effects, including the risk of kidney stones, have prompted further investigation into their safety profiles. In light of this, Eun Ha Kang, Seoul National University College of Medicine, Seongnam, Korea, and colleagues aimed to compare the risk of nephrolithiasis in type 2 diabetes patients who started treatment with SGLT2 inhibitors versus DPP4 inhibitors, separately analyzing those with no prior history of kidney stones (stone never-formers) and those with a history of kidney stones (stone ever-formers).
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.